CA2620248A1 - Chromenones et leur utilisation en tant que modulateurs des recepteurs metabotropes au glutamate - Google Patents
Chromenones et leur utilisation en tant que modulateurs des recepteurs metabotropes au glutamate Download PDFInfo
- Publication number
- CA2620248A1 CA2620248A1 CA002620248A CA2620248A CA2620248A1 CA 2620248 A1 CA2620248 A1 CA 2620248A1 CA 002620248 A CA002620248 A CA 002620248A CA 2620248 A CA2620248 A CA 2620248A CA 2620248 A1 CA2620248 A1 CA 2620248A1
- Authority
- CA
- Canada
- Prior art keywords
- 6alkyl
- chromen
- chloro
- cycloc3
- tetrahydrobenzo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 108010010914 Metabotropic glutamate receptors Proteins 0.000 title claims abstract description 31
- 102000016193 Metabotropic glutamate receptors Human genes 0.000 title claims abstract description 31
- 150000001875 compounds Chemical class 0.000 claims abstract description 274
- 238000000034 method Methods 0.000 claims abstract description 194
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical class C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 claims abstract description 16
- 230000002265 prevention Effects 0.000 claims abstract description 4
- -1 nitro, amino Chemical group 0.000 claims description 134
- 125000001072 heteroaryl group Chemical group 0.000 claims description 62
- 239000001257 hydrogen Substances 0.000 claims description 60
- 229910052739 hydrogen Inorganic materials 0.000 claims description 60
- 125000003118 aryl group Chemical group 0.000 claims description 59
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 49
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 48
- 229910052736 halogen Inorganic materials 0.000 claims description 41
- 150000002367 halogens Chemical class 0.000 claims description 41
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 36
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 34
- 229910052757 nitrogen Chemical group 0.000 claims description 32
- 229910052760 oxygen Inorganic materials 0.000 claims description 32
- 239000001301 oxygen Substances 0.000 claims description 31
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 239000004480 active ingredient Substances 0.000 claims description 26
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 26
- 229910052717 sulfur Inorganic materials 0.000 claims description 26
- 239000011593 sulfur Substances 0.000 claims description 26
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 25
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims description 25
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 25
- 125000001424 substituent group Chemical group 0.000 claims description 24
- 239000003814 drug Substances 0.000 claims description 23
- 125000005842 heteroatom Chemical group 0.000 claims description 21
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 21
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 20
- 125000001769 aryl amino group Chemical group 0.000 claims description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 201000010099 disease Diseases 0.000 claims description 19
- 239000000460 chlorine Substances 0.000 claims description 18
- 229930195712 glutamate Natural products 0.000 claims description 18
- 230000001225 therapeutic effect Effects 0.000 claims description 18
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 17
- 206010012289 Dementia Diseases 0.000 claims description 17
- 229910052801 chlorine Inorganic materials 0.000 claims description 17
- 239000011737 fluorine Substances 0.000 claims description 17
- 229910052731 fluorine Inorganic materials 0.000 claims description 17
- 230000002159 abnormal effect Effects 0.000 claims description 16
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 16
- 125000001246 bromo group Chemical group Br* 0.000 claims description 15
- 125000004432 carbon atom Chemical group C* 0.000 claims description 15
- 230000005062 synaptic transmission Effects 0.000 claims description 15
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 14
- 208000019901 Anxiety disease Diseases 0.000 claims description 14
- 208000023105 Huntington disease Diseases 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 14
- 125000003282 alkyl amino group Chemical group 0.000 claims description 14
- 230000008901 benefit Effects 0.000 claims description 14
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 201000006417 multiple sclerosis Diseases 0.000 claims description 13
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 claims description 12
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 12
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 12
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims description 12
- 208000010877 cognitive disease Diseases 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 12
- 125000004076 pyridyl group Chemical group 0.000 claims description 12
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 11
- 241000282414 Homo sapiens Species 0.000 claims description 11
- 208000008589 Obesity Diseases 0.000 claims description 11
- 208000018737 Parkinson disease Diseases 0.000 claims description 11
- 206010015037 epilepsy Diseases 0.000 claims description 11
- 235000020824 obesity Nutrition 0.000 claims description 11
- 206010010904 Convulsion Diseases 0.000 claims description 10
- 230000036461 convulsion Effects 0.000 claims description 10
- WFKAJVHLWXSISD-UHFFFAOYSA-N isobutyramide Chemical compound CC(C)C(N)=O WFKAJVHLWXSISD-UHFFFAOYSA-N 0.000 claims description 10
- 208000004296 neuralgia Diseases 0.000 claims description 10
- 208000021722 neuropathic pain Diseases 0.000 claims description 10
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 10
- 208000024827 Alzheimer disease Diseases 0.000 claims description 9
- 208000002193 Pain Diseases 0.000 claims description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 9
- 125000004043 oxo group Chemical group O=* 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 201000000980 schizophrenia Diseases 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 9
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 9
- MDEJOXDCIUMMGG-UHFFFAOYSA-N 2-nitro-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C([N+]([O-])=O)C(OC(C)C)=C1 MDEJOXDCIUMMGG-UHFFFAOYSA-N 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 8
- 208000004454 Hyperalgesia Diseases 0.000 claims description 8
- 208000028017 Psychotic disease Diseases 0.000 claims description 8
- 208000009205 Tinnitus Diseases 0.000 claims description 8
- 201000004810 Vascular dementia Diseases 0.000 claims description 8
- 208000006673 asthma Diseases 0.000 claims description 8
- 125000002393 azetidinyl group Chemical group 0.000 claims description 8
- 125000002619 bicyclic group Chemical group 0.000 claims description 8
- 125000002541 furyl group Chemical group 0.000 claims description 8
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 8
- 125000002757 morpholinyl group Chemical group 0.000 claims description 8
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 8
- 208000019906 panic disease Diseases 0.000 claims description 8
- 125000004193 piperazinyl group Chemical group 0.000 claims description 8
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 8
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 8
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 8
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 231100000886 tinnitus Toxicity 0.000 claims description 8
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims description 7
- 208000028698 Cognitive impairment Diseases 0.000 claims description 7
- 208000012661 Dyskinesia Diseases 0.000 claims description 7
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 125000004414 alkyl thio group Chemical group 0.000 claims description 7
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 claims description 7
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 7
- 125000002883 imidazolyl group Chemical group 0.000 claims description 7
- 208000002551 irritable bowel syndrome Diseases 0.000 claims description 7
- 208000024714 major depressive disease Diseases 0.000 claims description 7
- 125000002971 oxazolyl group Chemical group 0.000 claims description 7
- 125000000335 thiazolyl group Chemical group 0.000 claims description 7
- 125000000464 thioxo group Chemical group S=* 0.000 claims description 7
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 claims description 6
- AVYREWDYMQDSFQ-UHFFFAOYSA-N 2-chloro-3-propan-2-ylsulfanyl-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(SC(C)C)=C1 AVYREWDYMQDSFQ-UHFFFAOYSA-N 0.000 claims description 6
- CRLLNOWBEOYTDD-UHFFFAOYSA-N 2-chloro-7-methyl-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound CC1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(OC(C)C)=C1 CRLLNOWBEOYTDD-UHFFFAOYSA-N 0.000 claims description 6
- LDOTZWHLVLCDJY-UHFFFAOYSA-N 3-(adamantane-1-carbonyl)-7-bromochromen-2-one Chemical compound C1C(C2)CC(C3)CC2CC13C(=O)C1=CC2=CC=C(Br)C=C2OC1=O LDOTZWHLVLCDJY-UHFFFAOYSA-N 0.000 claims description 6
- 206010012335 Dependence Diseases 0.000 claims description 6
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 6
- 206010065390 Inflammatory pain Diseases 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 6
- 230000037410 cognitive enhancement Effects 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 6
- 210000000111 lower esophageal sphincter Anatomy 0.000 claims description 6
- 230000003287 optical effect Effects 0.000 claims description 6
- 239000012453 solvate Substances 0.000 claims description 6
- 208000011580 syndromic disease Diseases 0.000 claims description 6
- UAABTVVGFYIKLV-UHFFFAOYSA-N 2-chloro-3-methoxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(OC)=C1 UAABTVVGFYIKLV-UHFFFAOYSA-N 0.000 claims description 5
- LGJCMWPCKHUKOJ-UHFFFAOYSA-N 2-chloro-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(OC(C)C)=C1 LGJCMWPCKHUKOJ-UHFFFAOYSA-N 0.000 claims description 5
- AHYYPNSTNXRGIG-UHFFFAOYSA-N 3-(adamantane-1-carbonyl)-7-(diethylamino)chromen-2-one Chemical compound C1C(C2)CC(C3)CC2CC13C(=O)C1=CC2=CC=C(N(CC)CC)C=C2OC1=O AHYYPNSTNXRGIG-UHFFFAOYSA-N 0.000 claims description 5
- YZVGZFMXEWCBIO-UHFFFAOYSA-N 3-(adamantane-1-carbonyl)-7-methoxychromen-2-one Chemical compound C1C(C2)CC(C3)CC2CC13C(=O)C1=CC2=CC=C(OC)C=C2OC1=O YZVGZFMXEWCBIO-UHFFFAOYSA-N 0.000 claims description 5
- AXKFCVCCISFWBQ-UHFFFAOYSA-N 8-chloro-7-propan-2-yloxy-2,3-dihydro-1H-cyclopenta[c][1]benzopyran-4-one Chemical compound C1=2C=C(Cl)C(OC(C)C)=CC=2OC(=O)C2=C1CCC2 AXKFCVCCISFWBQ-UHFFFAOYSA-N 0.000 claims description 5
- LFPGVKREDIYQKR-UHFFFAOYSA-N 8-nitro-7-propan-2-yloxy-2,3-dihydro-1h-cyclopenta[c]chromen-4-one Chemical compound C1=2C=C([N+]([O-])=O)C(OC(C)C)=CC=2OC(=O)C2=C1CCC2 LFPGVKREDIYQKR-UHFFFAOYSA-N 0.000 claims description 5
- 206010052804 Drug tolerance Diseases 0.000 claims description 5
- 208000006264 Korsakoff syndrome Diseases 0.000 claims description 5
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims description 5
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims description 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 5
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 5
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 5
- 230000007278 cognition impairment Effects 0.000 claims description 5
- 210000003027 ear inner Anatomy 0.000 claims description 5
- 125000005368 heteroarylthio group Chemical group 0.000 claims description 5
- 208000028867 ischemia Diseases 0.000 claims description 5
- 229940047889 isobutyramide Drugs 0.000 claims description 5
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 5
- 230000004112 neuroprotection Effects 0.000 claims description 5
- WFLXVBRQAJUJCV-UHFFFAOYSA-N s-[(2-chloro-6-oxo-7,8,9,10-tetrahydrobenzo[c]chromen-3-yl)] n,n-dimethylcarbamothioate Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(SC(=O)N(C)C)=C1 WFLXVBRQAJUJCV-UHFFFAOYSA-N 0.000 claims description 5
- NXHGVPZDBUCJHE-UHFFFAOYSA-N s-[(2-chloro-9-methyl-6-oxo-7,8,9,10-tetrahydrobenzo[c]chromen-3-yl)] n,n-dimethylcarbamothioate Chemical compound C12=CC(Cl)=C(SC(=O)N(C)C)C=C2OC(=O)C2=C1CC(C)CC2 NXHGVPZDBUCJHE-UHFFFAOYSA-N 0.000 claims description 5
- IHAGBKZSQYZULC-UHFFFAOYSA-N 2-chloro-3-propan-2-yloxy-8-(trifluoromethyl)-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1C(C(F)(F)F)CCC2=C1C(=O)OC1=C2C=C(Cl)C(OC(C)C)=C1 IHAGBKZSQYZULC-UHFFFAOYSA-N 0.000 claims description 4
- FLDKKCWIQGVKBF-UHFFFAOYSA-N 2-chloro-9-methyl-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CC(C)CC2=C1C(=O)OC1=C2C=C(Cl)C(OC(C)C)=C1 FLDKKCWIQGVKBF-UHFFFAOYSA-N 0.000 claims description 4
- CBUFSYSVBJKAOZ-UHFFFAOYSA-N 2-ethyl-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(C=C(C(=C1)OC(C)C)CC)=C1OC2=O CBUFSYSVBJKAOZ-UHFFFAOYSA-N 0.000 claims description 4
- IKSDSFGFVUMVEA-UHFFFAOYSA-N 3-(adamantane-1-carbonyl)-7-(dimethylamino)chromen-2-one Chemical compound C1C(C2)CC(C3)CC2CC13C(=O)C1=CC2=CC=C(N(C)C)C=C2OC1=O IKSDSFGFVUMVEA-UHFFFAOYSA-N 0.000 claims description 4
- 206010065040 AIDS dementia complex Diseases 0.000 claims description 4
- 208000008811 Agoraphobia Diseases 0.000 claims description 4
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 4
- 206010003805 Autism Diseases 0.000 claims description 4
- 208000020706 Autistic disease Diseases 0.000 claims description 4
- 208000020925 Bipolar disease Diseases 0.000 claims description 4
- 241001115070 Bornavirus Species 0.000 claims description 4
- 206010006550 Bulimia nervosa Diseases 0.000 claims description 4
- 206010012218 Delirium Diseases 0.000 claims description 4
- 208000024254 Delusional disease Diseases 0.000 claims description 4
- 201000010374 Down Syndrome Diseases 0.000 claims description 4
- 208000014094 Dystonic disease Diseases 0.000 claims description 4
- 208000030814 Eating disease Diseases 0.000 claims description 4
- 208000020564 Eye injury Diseases 0.000 claims description 4
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 4
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 4
- 208000011688 Generalised anxiety disease Diseases 0.000 claims description 4
- 208000010412 Glaucoma Diseases 0.000 claims description 4
- 208000032612 Glial tumor Diseases 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 4
- 208000031886 HIV Infections Diseases 0.000 claims description 4
- 208000010496 Heart Arrest Diseases 0.000 claims description 4
- 208000035154 Hyperesthesia Diseases 0.000 claims description 4
- 208000013016 Hypoglycemia Diseases 0.000 claims description 4
- 206010021143 Hypoxia Diseases 0.000 claims description 4
- 201000008197 Laryngitis Diseases 0.000 claims description 4
- 208000019693 Lung disease Diseases 0.000 claims description 4
- 208000021891 Micturition disease Diseases 0.000 claims description 4
- 208000019695 Migraine disease Diseases 0.000 claims description 4
- 208000016285 Movement disease Diseases 0.000 claims description 4
- 208000007101 Muscle Cramp Diseases 0.000 claims description 4
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 4
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims description 4
- 102000029797 Prion Human genes 0.000 claims description 4
- 108091000054 Prion Proteins 0.000 claims description 4
- 208000003251 Pruritus Diseases 0.000 claims description 4
- 206010067171 Regurgitation Diseases 0.000 claims description 4
- 206010057190 Respiratory tract infections Diseases 0.000 claims description 4
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 4
- 208000017442 Retinal disease Diseases 0.000 claims description 4
- 206010038923 Retinopathy Diseases 0.000 claims description 4
- 208000020186 Schizophreniform disease Diseases 0.000 claims description 4
- 206010041250 Social phobia Diseases 0.000 claims description 4
- 208000005392 Spasm Diseases 0.000 claims description 4
- 208000011963 Substance-induced psychotic disease Diseases 0.000 claims description 4
- 231100000393 Substance-induced psychotic disorder Toxicity 0.000 claims description 4
- 208000034799 Tauopathies Diseases 0.000 claims description 4
- 206010044688 Trisomy 21 Diseases 0.000 claims description 4
- 206010046543 Urinary incontinence Diseases 0.000 claims description 4
- 206010047700 Vomiting Diseases 0.000 claims description 4
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 4
- 206010053552 allodynia Diseases 0.000 claims description 4
- 230000036506 anxiety Effects 0.000 claims description 4
- 208000029028 brain injury Diseases 0.000 claims description 4
- 201000009243 chronic laryngitis Diseases 0.000 claims description 4
- 230000019771 cognition Effects 0.000 claims description 4
- 208000017004 dementia pugilistica Diseases 0.000 claims description 4
- 235000014632 disordered eating Nutrition 0.000 claims description 4
- 201000006549 dyspepsia Diseases 0.000 claims description 4
- 208000010118 dystonia Diseases 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 210000001652 frontal lobe Anatomy 0.000 claims description 4
- 208000029364 generalized anxiety disease Diseases 0.000 claims description 4
- 210000003128 head Anatomy 0.000 claims description 4
- 208000007386 hepatic encephalopathy Diseases 0.000 claims description 4
- 150000004677 hydrates Chemical class 0.000 claims description 4
- 208000013403 hyperactivity Diseases 0.000 claims description 4
- 230000007954 hypoxia Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 208000014674 injury Diseases 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 206010027599 migraine Diseases 0.000 claims description 4
- 230000004065 mitochondrial dysfunction Effects 0.000 claims description 4
- 125000002950 monocyclic group Chemical group 0.000 claims description 4
- 208000005264 motor neuron disease Diseases 0.000 claims description 4
- KFVLOKHTHRBGHW-UHFFFAOYSA-N n-acetyl-n-(2-chloro-6-oxo-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-4-yl)acetamide Chemical compound C1CCCC2=C1C1=CC(Cl)=C(OC(C)C)C(N(C(C)=O)C(C)=O)=C1OC2=O KFVLOKHTHRBGHW-UHFFFAOYSA-N 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 208000018360 neuromuscular disease Diseases 0.000 claims description 4
- 229940005483 opioid analgesics Drugs 0.000 claims description 4
- 208000002851 paranoid schizophrenia Diseases 0.000 claims description 4
- 125000003386 piperidinyl group Chemical group 0.000 claims description 4
- 230000002980 postoperative effect Effects 0.000 claims description 4
- 230000001823 pruritic effect Effects 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 208000022610 schizoaffective disease Diseases 0.000 claims description 4
- 208000019116 sleep disease Diseases 0.000 claims description 4
- 208000018198 spasticity Diseases 0.000 claims description 4
- 208000020431 spinal cord injury Diseases 0.000 claims description 4
- 230000008733 trauma Effects 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- 210000001635 urinary tract Anatomy 0.000 claims description 4
- 230000002792 vascular Effects 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 230000008673 vomiting Effects 0.000 claims description 4
- 125000004750 (C1-C6) alkylaminosulfonyl group Chemical group 0.000 claims description 3
- PLFFZXKNWRZJAZ-UHFFFAOYSA-N 2-chloro-3-(difluoromethoxy)-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(OC(F)F)=C1 PLFFZXKNWRZJAZ-UHFFFAOYSA-N 0.000 claims description 3
- SPFHWEDDUZPSPY-UHFFFAOYSA-N 2-chloro-3-pyridin-2-ylsulfanyl-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound ClC1=CC=2C=3CCCCC=3C(=O)OC=2C=C1SC1=CC=CC=N1 SPFHWEDDUZPSPY-UHFFFAOYSA-N 0.000 claims description 3
- HHXKYEDQUFTABT-UHFFFAOYSA-N 3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C1=CC=C(OC(C)C)C=C1OC2=O HHXKYEDQUFTABT-UHFFFAOYSA-N 0.000 claims description 3
- KLGZOTKVIMZRON-UHFFFAOYSA-N 6-chloro-3-imidazo[1,2-a]pyridin-2-ylchromen-2-one Chemical compound C1=CC=CC2=NC(C=3C(=O)OC4=CC=C(C=C4C=3)Cl)=CN21 KLGZOTKVIMZRON-UHFFFAOYSA-N 0.000 claims description 3
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 3
- 206010008748 Chorea Diseases 0.000 claims description 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 3
- 125000005108 alkenylthio group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 150000005347 biaryls Chemical group 0.000 claims description 3
- 208000014679 binge eating disease Diseases 0.000 claims description 3
- 208000012601 choreatic disease Diseases 0.000 claims description 3
- 230000001037 epileptic effect Effects 0.000 claims description 3
- FNUNQZDGUXOIJI-UHFFFAOYSA-N o-[(6-oxo-7,8,9,10-tetrahydrobenzo[c]chromen-3-yl)] n,n-dimethylcarbamothioate Chemical compound C1CCCC2=C1C1=CC=C(OC(=S)N(C)C)C=C1OC2=O FNUNQZDGUXOIJI-UHFFFAOYSA-N 0.000 claims description 3
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 claims description 3
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- 201000008914 temporal lobe epilepsy Diseases 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 125000006168 tricyclic group Chemical group 0.000 claims description 3
- LXXKMMYOKFJCDZ-UHFFFAOYSA-N 2,3-dimethoxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(OC)C(OC)=C1 LXXKMMYOKFJCDZ-UHFFFAOYSA-N 0.000 claims description 2
- UXKQESFXXWWMDU-UHFFFAOYSA-N 2-chloro-3-(3-methylbut-2-enoxy)-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(OCC=C(C)C)=C1 UXKQESFXXWWMDU-UHFFFAOYSA-N 0.000 claims description 2
- AVPPJDILAWUJQX-UHFFFAOYSA-N 2-chloro-3-[(2-chlorophenyl)methoxy]-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound ClC1=CC=CC=C1COC(C(=C1)Cl)=CC2=C1C(CCCC1)=C1C(=O)O2 AVPPJDILAWUJQX-UHFFFAOYSA-N 0.000 claims description 2
- PIZFKAWPTPSHFH-UHFFFAOYSA-N 2-chloro-3-hydroxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(O)=C1 PIZFKAWPTPSHFH-UHFFFAOYSA-N 0.000 claims description 2
- ADLNFHHRTMBRFD-UHFFFAOYSA-N 2-chloro-3-hydroxy-9-methyl-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C12=CC(Cl)=C(O)C=C2OC(=O)C2=C1CC(C)CC2 ADLNFHHRTMBRFD-UHFFFAOYSA-N 0.000 claims description 2
- ZAEWDKBDPROWRW-UHFFFAOYSA-N 2-chloro-4-[(dimethylazaniumyl)methyl]-6-oxo-7,8,9,10-tetrahydrobenzo[c]chromen-3-olate Chemical compound C1CCCC2=C1C(C=C(Cl)C(O)=C1CN(C)C)=C1OC2=O ZAEWDKBDPROWRW-UHFFFAOYSA-N 0.000 claims description 2
- ULRCJDZFIIRZIM-UHFFFAOYSA-N 2-ethyl-3-hydroxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(C=C(C(=C1)O)CC)=C1OC2=O ULRCJDZFIIRZIM-UHFFFAOYSA-N 0.000 claims description 2
- SXNLGAZYLFEUAA-UHFFFAOYSA-N 2-hexyl-3-methoxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(C=C(C(=C1)OC)CCCCCC)=C1OC2=O SXNLGAZYLFEUAA-UHFFFAOYSA-N 0.000 claims description 2
- HBGSSPMHBRVPST-UHFFFAOYSA-N 2-hydroxy-3-methoxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(O)C(OC)=C1 HBGSSPMHBRVPST-UHFFFAOYSA-N 0.000 claims description 2
- USIQBZCKWWHMJB-UHFFFAOYSA-N 3-(1-phenylethoxy)benzo[c]chromen-6-one Chemical compound C=1C=C(C2=CC=CC=C2C(=O)O2)C2=CC=1OC(C)C1=CC=CC=C1 USIQBZCKWWHMJB-UHFFFAOYSA-N 0.000 claims description 2
- MWJOYFWECOYZJN-UHFFFAOYSA-N 3-(adamantane-1-carbonyl)-6-bromochromen-2-one Chemical compound C1C(C2)CC(C3)CC2CC13C(=O)C1=CC2=CC(Br)=CC=C2OC1=O MWJOYFWECOYZJN-UHFFFAOYSA-N 0.000 claims description 2
- VEUZUGIGGNOWBW-UHFFFAOYSA-N 3-(adamantane-1-carbonyl)-6-methoxychromen-2-one Chemical compound C1C(C2)CC(C3)CC2CC13C(=O)C1=CC2=CC(OC)=CC=C2OC1=O VEUZUGIGGNOWBW-UHFFFAOYSA-N 0.000 claims description 2
- UPNUPZWUUYFYCS-UHFFFAOYSA-N 3-(adamantane-1-carbonyl)chromen-2-one Chemical compound C1C(C2)CC(C3)CC2CC13C(=O)C1=CC2=CC=CC=C2OC1=O UPNUPZWUUYFYCS-UHFFFAOYSA-N 0.000 claims description 2
- OSCCXVQIFIYINI-UHFFFAOYSA-N 3-(propan-2-ylamino)-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C1=CC=C(NC(C)C)C=C1OC2=O OSCCXVQIFIYINI-UHFFFAOYSA-N 0.000 claims description 2
- GHZLYPVLYPJULD-UHFFFAOYSA-N 3-amino-2-chloro-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(N)=C1 GHZLYPVLYPJULD-UHFFFAOYSA-N 0.000 claims description 2
- LAYVHHGTSFKWDD-UHFFFAOYSA-N 3-amino-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C1=CC=C(N)C=C1OC2=O LAYVHHGTSFKWDD-UHFFFAOYSA-N 0.000 claims description 2
- DCHFPDPBVJROEJ-UHFFFAOYSA-N 3-hydroxy-4-(piperidin-1-ylmethyl)-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound OC1=CC=C2C=3CCCCC=3C(=O)OC2=C1CN1CCCCC1 DCHFPDPBVJROEJ-UHFFFAOYSA-N 0.000 claims description 2
- KPOWIEQVQGIGRH-UHFFFAOYSA-N 4-[(2-chloro-6-oxo-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-4-yl)amino]-4-oxobutanoic acid Chemical compound C1CCCC2=C1C1=CC(Cl)=C(OC(C)C)C(NC(=O)CCC(O)=O)=C1OC2=O KPOWIEQVQGIGRH-UHFFFAOYSA-N 0.000 claims description 2
- AJOANILONFCHFL-UHFFFAOYSA-N 6-chloro-7-hydroxy-4-(trifluoromethyl)chromen-2-one Chemical compound O1C(=O)C=C(C(F)(F)F)C2=C1C=C(O)C(Cl)=C2 AJOANILONFCHFL-UHFFFAOYSA-N 0.000 claims description 2
- HETUGUSWOXYKSY-UHFFFAOYSA-N 8-chloro-7-hydroxy-2,3-dihydro-1h-cyclopenta[c]chromen-4-one Chemical compound C1=2C=C(Cl)C(O)=CC=2OC(=O)C2=C1CCC2 HETUGUSWOXYKSY-UHFFFAOYSA-N 0.000 claims description 2
- CUQRMRTXIDBXOS-UHFFFAOYSA-N 8-hexyl-7-methoxy-2,3-dihydro-1h-cyclopenta[c]chromen-4-one Chemical compound C1=2CCCC=2C(=O)OC2=C1C=C(CCCCCC)C(OC)=C2 CUQRMRTXIDBXOS-UHFFFAOYSA-N 0.000 claims description 2
- UTXNNSLVZKRVOW-UHFFFAOYSA-N 8-propan-2-yloxy-1,2,3,4-tetrahydrochromeno[3,4-c]pyridin-5-one Chemical compound C1CNCC2=C1C1=CC=C(OC(C)C)C=C1OC2=O UTXNNSLVZKRVOW-UHFFFAOYSA-N 0.000 claims description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 2
- 206010058019 Cancer Pain Diseases 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000016620 Tourette disease Diseases 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 201000009032 substance abuse Diseases 0.000 claims description 2
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 2
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000029197 Amphetamine-Related disease Diseases 0.000 claims 2
- 208000022497 Cocaine-Related disease Diseases 0.000 claims 2
- 206010013654 Drug abuse Diseases 0.000 claims 2
- 208000026251 Opioid-Related disease Diseases 0.000 claims 2
- ZBUQQKVYDUHVLQ-UHFFFAOYSA-N 11-chloro-2-propan-2-ylsulfanyl-6,7,8,9-tetrahydroisochromeno[3,4-e][1,3]benzoxazol-5-one Chemical compound C1CCCC2=C1C(C=C(Cl)C1=C3N=C(O1)SC(C)C)=C3OC2=O ZBUQQKVYDUHVLQ-UHFFFAOYSA-N 0.000 claims 1
- INRMSLZELQFEHY-UHFFFAOYSA-N 2-chloro-3-hydroxy-4-(morpholin-4-ylmethyl)-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound OC1=C(Cl)C=C2C=3CCCCC=3C(=O)OC2=C1CN1CCOCC1 INRMSLZELQFEHY-UHFFFAOYSA-N 0.000 claims 1
- HAZMZKQLSLJMNY-UHFFFAOYSA-N 3-[(2-chlorophenyl)methoxy]-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound ClC1=CC=CC=C1COC1=CC=C(C2=C(CCCC2)C(=O)O2)C2=C1 HAZMZKQLSLJMNY-UHFFFAOYSA-N 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims 1
- 206010057852 Nicotine dependence Diseases 0.000 claims 1
- 208000025569 Tobacco Use disease Diseases 0.000 claims 1
- 206010043903 Tobacco abuse Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 206010001584 alcohol abuse Diseases 0.000 claims 1
- 208000025746 alcohol use disease Diseases 0.000 claims 1
- 201000002472 amphetamine abuse Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 201000001272 cocaine abuse Diseases 0.000 claims 1
- 201000006145 cocaine dependence Diseases 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 201000005040 opiate dependence Diseases 0.000 claims 1
- 208000033300 perinatal asphyxia Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 13
- 230000001154 acute effect Effects 0.000 abstract description 5
- 230000001684 chronic effect Effects 0.000 abstract description 5
- 230000008569 process Effects 0.000 abstract description 3
- 208000012902 Nervous system disease Diseases 0.000 abstract description 2
- 208000025966 Neurological disease Diseases 0.000 abstract description 2
- 239000000203 mixture Substances 0.000 description 46
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 23
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 150000002431 hydrogen Chemical group 0.000 description 21
- 238000009472 formulation Methods 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 18
- 239000007788 liquid Substances 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- CDAWCLOXVUBKRW-UHFFFAOYSA-N 2-aminophenol Chemical compound NC1=CC=CC=C1O CDAWCLOXVUBKRW-UHFFFAOYSA-N 0.000 description 12
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 12
- 239000003826 tablet Substances 0.000 description 12
- 229940049906 glutamate Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 10
- 229910000027 potassium carbonate Inorganic materials 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 108020003175 receptors Proteins 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 239000002253 acid Substances 0.000 description 9
- 125000003277 amino group Chemical group 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 229960000367 inositol Drugs 0.000 description 9
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000000556 agonist Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 235000019441 ethanol Nutrition 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 210000001130 astrocyte Anatomy 0.000 description 7
- 239000003085 diluting agent Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- NEWKHUASLBMWRE-UHFFFAOYSA-N 2-methyl-6-(phenylethynyl)pyridine Chemical compound CC1=CC=CC(C#CC=2C=CC=CC=2)=N1 NEWKHUASLBMWRE-UHFFFAOYSA-N 0.000 description 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- 238000005804 alkylation reaction Methods 0.000 description 6
- 239000005557 antagonist Substances 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 239000000969 carrier Substances 0.000 description 6
- 210000003169 central nervous system Anatomy 0.000 description 6
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 125000001153 fluoro group Chemical group F* 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 6
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 230000029936 alkylation Effects 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 231100000252 nontoxic Toxicity 0.000 description 5
- 230000003000 nontoxic effect Effects 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000008213 purified water Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- UOUSVOLPRYKHCC-UHFFFAOYSA-N (6-oxo-7,8,9,10-tetrahydrobenzo[c]chromen-3-yl) 2,2-dimethylpropanoate Chemical compound C1CCCC2=C1C1=CC=C(OC(=O)C(C)(C)C)C=C1OC2=O UOUSVOLPRYKHCC-UHFFFAOYSA-N 0.000 description 4
- UMURLIQHQSKULR-UHFFFAOYSA-N 1,3-oxazolidine-2-thione Chemical compound S=C1NCCO1 UMURLIQHQSKULR-UHFFFAOYSA-N 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
- MTVWFVDWRVYDOR-UHFFFAOYSA-N 3,4-Dihydroxyphenylglycol Chemical compound OCC(O)C1=CC=C(O)C(O)=C1 MTVWFVDWRVYDOR-UHFFFAOYSA-N 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 239000007995 HEPES buffer Substances 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 238000009833 condensation Methods 0.000 description 4
- 230000005494 condensation Effects 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 229910017604 nitric acid Inorganic materials 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 235000015320 potassium carbonate Nutrition 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 3
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 3
- DTBDAFLSBDGPEA-UHFFFAOYSA-N 3-Methylquinoline Natural products C1=CC=CC2=CC(C)=CN=C21 DTBDAFLSBDGPEA-UHFFFAOYSA-N 0.000 description 3
- YTCVPEZECJYZRK-UHFFFAOYSA-N 3-nitrochromen-2-one Chemical compound C1=CC=C2OC(=O)C([N+](=O)[O-])=CC2=C1 YTCVPEZECJYZRK-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 241000575946 Ione Species 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 description 3
- 108010065028 Metabotropic Glutamate 5 Receptor Proteins 0.000 description 3
- 102100038357 Metabotropic glutamate receptor 5 Human genes 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920000954 Polyglycolide Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000013543 active substance Substances 0.000 description 3
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 3
- 229940025084 amphetamine Drugs 0.000 description 3
- 238000006254 arylation reaction Methods 0.000 description 3
- 239000002585 base Chemical class 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 208000015114 central nervous system disease Diseases 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229960003920 cocaine Drugs 0.000 description 3
- RAFNCPHFRHZCPS-UHFFFAOYSA-N di(imidazol-1-yl)methanethione Chemical compound C1=CN=CN1C(=S)N1C=CN=C1 RAFNCPHFRHZCPS-UHFFFAOYSA-N 0.000 description 3
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000005567 liquid scintillation counting Methods 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229960002715 nicotine Drugs 0.000 description 3
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 3
- 238000006396 nitration reaction Methods 0.000 description 3
- 150000002828 nitro derivatives Chemical class 0.000 description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 description 3
- 229940127240 opiate Drugs 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000009984 peri-natal effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000004633 polyglycolic acid Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- JDVPQXZIJDEHAN-UHFFFAOYSA-N succinamic acid Chemical compound NC(=O)CCC(O)=O JDVPQXZIJDEHAN-UHFFFAOYSA-N 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 3
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 3
- YTSLMMORKHRKFV-UHFFFAOYSA-N (2-chloro-6-oxo-7,8,9,10-tetrahydrobenzo[c]chromen-3-yl) acetate Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(OC(=O)C)=C1 YTSLMMORKHRKFV-UHFFFAOYSA-N 0.000 description 2
- HZIYKCGEJUBNHP-UHFFFAOYSA-N (2-chloro-6-oxo-7,8,9,10-tetrahydrobenzo[c]chromen-3-yl) trifluoromethanesulfonate Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(OS(=O)(=O)C(F)(F)F)=C1 HZIYKCGEJUBNHP-UHFFFAOYSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- DNVLNUFKUREZMR-UHFFFAOYSA-N 1-(6-oxo-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-4-yl)-3-phenylurea Chemical compound CC(C)OC1=CC=C2C=3CCCCC=3C(=O)OC2=C1NC(=O)NC1=CC=CC=C1 DNVLNUFKUREZMR-UHFFFAOYSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- PWQSIZMBRFGCRV-UHFFFAOYSA-N 11-chloro-6,7,8,9-tetrahydroisochromeno[3,4-e][1,3]benzoxazol-5-one Chemical compound C1CCCC2=C1C(C=C(C=1OC=NC=11)Cl)=C1OC2=O PWQSIZMBRFGCRV-UHFFFAOYSA-N 0.000 description 2
- UJPJRTBOMKEYEH-UHFFFAOYSA-N 2-(2-hydroxyethoxy)-3-methoxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(OCCO)C(OC)=C1 UJPJRTBOMKEYEH-UHFFFAOYSA-N 0.000 description 2
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 2
- RIKJDWVJTRULIR-UHFFFAOYSA-N 2-chloro-3-(2-hydroxyethoxy)-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(OCCO)=C1 RIKJDWVJTRULIR-UHFFFAOYSA-N 0.000 description 2
- WZRRKVMCPPCNJC-UHFFFAOYSA-N 2-chloro-3-(3-chloro-2-hydroxypropoxy)-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(OCC(CCl)O)=C1 WZRRKVMCPPCNJC-UHFFFAOYSA-N 0.000 description 2
- OGIHXUFMZPZUNL-UHFFFAOYSA-N 2-chloro-3-(4-methoxycyclohexyl)oxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CC(OC)CCC1OC(C(=C1)Cl)=CC2=C1C(CCCC1)=C1C(=O)O2 OGIHXUFMZPZUNL-UHFFFAOYSA-N 0.000 description 2
- HFLDOJPKIPKPQU-UHFFFAOYSA-N 2-chloro-3-(cyclobutylmethoxy)-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound ClC1=CC=2C=3CCCCC=3C(=O)OC=2C=C1OCC1CCC1 HFLDOJPKIPKPQU-UHFFFAOYSA-N 0.000 description 2
- FTIVIICRUCAALA-UHFFFAOYSA-N 2-chloro-3-[2-hydroxy-3-(propan-2-ylamino)propoxy]-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(OCC(O)CNC(C)C)=C1 FTIVIICRUCAALA-UHFFFAOYSA-N 0.000 description 2
- NTTXMDOOOWQIOI-UHFFFAOYSA-N 2-chloro-3-ethoxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(OCC)=C1 NTTXMDOOOWQIOI-UHFFFAOYSA-N 0.000 description 2
- RRYJDKXTVHMCFI-UHFFFAOYSA-N 2-chloro-3-hydroxy-4-nitro-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C1=CC(Cl)=C(O)C([N+]([O-])=O)=C1OC2=O RRYJDKXTVHMCFI-UHFFFAOYSA-N 0.000 description 2
- VQESEWUTGDEUOA-UHFFFAOYSA-N 2-chloro-3-methylsulfonyl-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(S(=O)(=O)C)=C1 VQESEWUTGDEUOA-UHFFFAOYSA-N 0.000 description 2
- YOISIQFUKDOUDK-UHFFFAOYSA-N 2-chloro-3-propan-2-yloxy-9-pyridin-2-yl-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1C=2C=3C=C(Cl)C(OC(C)C)=CC=3OC(=O)C=2CCC1C1=CC=CC=N1 YOISIQFUKDOUDK-UHFFFAOYSA-N 0.000 description 2
- JQAAAASWQJDDCN-UHFFFAOYSA-N 2-chloro-4-(morpholin-4-ylmethyl)-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound CC(C)OC1=C(Cl)C=C2C=3CCCCC=3C(=O)OC2=C1CN1CCOCC1 JQAAAASWQJDDCN-UHFFFAOYSA-N 0.000 description 2
- SNURJEHJLWPHMS-UHFFFAOYSA-N 2-ethoxy-4-methoxy-8,9,10,11-tetrahydroisochromeno[4,3-e][1,3]benzoxazol-7-one Chemical compound C1CCCC2=C1C(=O)OC(C=C1OC)=C2C2=C1OC(OCC)=N2 SNURJEHJLWPHMS-UHFFFAOYSA-N 0.000 description 2
- GIBUDPZMAQGYPI-UHFFFAOYSA-N 2-methoxy-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(C=C(C(=C1)OC(C)C)OC)=C1OC2=O GIBUDPZMAQGYPI-UHFFFAOYSA-N 0.000 description 2
- XKUIDCXALUDLPN-UHFFFAOYSA-N 2-methyl-n-(2-methylpropanoyl)-n-(6-oxo-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-2-yl)propanamide Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(N(C(=O)C(C)C)C(=O)C(C)C)C(OC(C)C)=C1 XKUIDCXALUDLPN-UHFFFAOYSA-N 0.000 description 2
- ODMFMUXNUUGZAO-UHFFFAOYSA-N 3-(benzylamino)-2-chloro-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound ClC1=CC=2C=3CCCCC=3C(=O)OC=2C=C1NCC1=CC=CC=C1 ODMFMUXNUUGZAO-UHFFFAOYSA-N 0.000 description 2
- NXPRGDRIKIWAGQ-UHFFFAOYSA-N 3-acetyl-2-chloro-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(C(=O)C)=C1 NXPRGDRIKIWAGQ-UHFFFAOYSA-N 0.000 description 2
- XMNPGKMPVWHZBI-UHFFFAOYSA-N 3-benzyl-8-propan-2-yloxy-2,4-dihydro-1h-chromeno[3,4-c]pyridin-5-one Chemical compound C1C=2C(=O)OC3=CC(OC(C)C)=CC=C3C=2CCN1CC1=CC=CC=C1 XMNPGKMPVWHZBI-UHFFFAOYSA-N 0.000 description 2
- HCRSFALOFNWSBA-UHFFFAOYSA-N 3-methoxy-2-pyridin-2-yl-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound COC1=CC=2OC(=O)C=3CCCCC=3C=2C=C1C1=CC=CC=N1 HCRSFALOFNWSBA-UHFFFAOYSA-N 0.000 description 2
- GYAIZQKBONVDEJ-UHFFFAOYSA-N 4-amino-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C1=CC=C(OC(C)C)C(N)=C1OC2=O GYAIZQKBONVDEJ-UHFFFAOYSA-N 0.000 description 2
- YZMLQCMDXAIIGS-UHFFFAOYSA-N 4-methoxy-2-methylsulfanyl-8,9,10,11-tetrahydroisochromeno[4,3-e][1,3]benzoxazol-7-one Chemical compound C1CCCC2=C1C(=O)OC(C=C1OC)=C2C2=C1OC(SC)=N2 YZMLQCMDXAIIGS-UHFFFAOYSA-N 0.000 description 2
- IPFNKZFXDXIBTH-UHFFFAOYSA-N 4-methoxy-2-phenyl-8,9,10,11-tetrahydroisochromeno[4,3-e][1,3]benzoxazol-7-one Chemical compound O1C=2C(OC)=CC=3OC(=O)C=4CCCCC=4C=3C=2N=C1C1=CC=CC=C1 IPFNKZFXDXIBTH-UHFFFAOYSA-N 0.000 description 2
- CGOQDMRNJXYGPI-UHFFFAOYSA-N 4-methyl-n-(6-oxo-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-2-yl)benzenesulfonamide Chemical compound CC(C)OC1=CC=2OC(=O)C=3CCCCC=3C=2C=C1NS(=O)(=O)C1=CC=C(C)C=C1 CGOQDMRNJXYGPI-UHFFFAOYSA-N 0.000 description 2
- LBSCHTGXMDEODE-UHFFFAOYSA-N 4-nitro-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C1=CC=C(OC(C)C)C([N+]([O-])=O)=C1OC2=O LBSCHTGXMDEODE-UHFFFAOYSA-N 0.000 description 2
- OYEFBWPCUYYOQG-UHFFFAOYSA-N 6,7,8,9-tetrahydro-3H-isochromeno[3,4-e][1,3]benzoxazole-2,5-dione Chemical compound C1CCCC=2C(OC3=C4NC(OC4=CC=C3C12)=O)=O OYEFBWPCUYYOQG-UHFFFAOYSA-N 0.000 description 2
- OWNKUGFADJBTSR-UHFFFAOYSA-N 6,7,8,9-tetrahydroisochromeno[3,4-e][1,3]benzoxazol-5-one Chemical compound C1CCCC=2C(OC3=C4N=COC4=CC=C3C12)=O OWNKUGFADJBTSR-UHFFFAOYSA-N 0.000 description 2
- UNYWQCLDGMDCCN-UHFFFAOYSA-N 6-chloro-7-hydroxy-4-pyridin-3-ylchromen-2-one Chemical compound C1=2C=C(Cl)C(O)=CC=2OC(=O)C=C1C1=CC=CN=C1 UNYWQCLDGMDCCN-UHFFFAOYSA-N 0.000 description 2
- WQCZATGLJCRIDV-UHFFFAOYSA-N 6-chloro-7-hydroxy-4-pyridin-4-ylchromen-2-one Chemical compound C1=2C=C(Cl)C(O)=CC=2OC(=O)C=C1C1=CC=NC=C1 WQCZATGLJCRIDV-UHFFFAOYSA-N 0.000 description 2
- KAAQPWVPEDDZAJ-UHFFFAOYSA-N 6-phenyl-4,17-dioxa-7-azatetracyclo[8.7.0.03,8.011,15]heptadeca-1,3(8),6,9,11(15)-pentaene-5,16-dione Chemical compound N=1C2=CC=3C=4CCCC=4C(=O)OC=3C=C2OC(=O)C=1C1=CC=CC=C1 KAAQPWVPEDDZAJ-UHFFFAOYSA-N 0.000 description 2
- ORCPAHYRAWLMNV-UHFFFAOYSA-N 7-[(3-phenoxyphenyl)methoxy]-4-phenylchromen-2-one Chemical compound C12=CC=C(OCC=3C=C(OC=4C=CC=CC=4)C=CC=3)C=C2OC(=O)C=C1C1=CC=CC=C1 ORCPAHYRAWLMNV-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- OXPNQYXROHKDNM-UHFFFAOYSA-N 9-propan-2-ylsulfanyl-1,2,3,4-tetrahydroisochromeno[4,3-f][1,3]benzoxazol-5-one Chemical compound C1CCCC2=C1C(C=C1N=C(OC1=C1)SC(C)C)=C1OC2=O OXPNQYXROHKDNM-UHFFFAOYSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 2
- HOOWCUZPEFNHDT-UHFFFAOYSA-N DHPG Natural products OC(=O)C(N)C1=CC(O)=CC(O)=C1 HOOWCUZPEFNHDT-UHFFFAOYSA-N 0.000 description 2
- 102000016911 Deoxyribonucleases Human genes 0.000 description 2
- 108010053770 Deoxyribonucleases Proteins 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 239000004280 Sodium formate Substances 0.000 description 2
- 241001061127 Thione Species 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001263 acyl chlorides Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001502 aryl halides Chemical class 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229910021538 borax Inorganic materials 0.000 description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical compound C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 description 2
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940127271 compound 49 Drugs 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000001054 cortical effect Effects 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 description 2
- ZXSBDSGRQIWJPM-UHFFFAOYSA-N dimethylcarbamothioic s-acid Chemical compound CN(C)C(S)=O ZXSBDSGRQIWJPM-UHFFFAOYSA-N 0.000 description 2
- UQGFMSUEHSUPRD-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane Chemical compound [Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 UQGFMSUEHSUPRD-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 235000019256 formaldehyde Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- GTABPIFMSFFGGA-UHFFFAOYSA-N n-(6-oxo-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-2-yl)methanesulfonamide Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(NS(C)(=O)=O)C(OC(C)C)=C1 GTABPIFMSFFGGA-UHFFFAOYSA-N 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 150000002916 oxazoles Chemical class 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001592 potato starch Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011347 resin Substances 0.000 description 2
- 229920005989 resin Polymers 0.000 description 2
- 238000010956 selective crystallization Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 2
- 235000019254 sodium formate Nutrition 0.000 description 2
- 239000004328 sodium tetraborate Substances 0.000 description 2
- 235000010339 sodium tetraborate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 125000003638 stannyl group Chemical group [H][Sn]([H])([H])* 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000002511 suppository base Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000007916 tablet composition Substances 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100001274 therapeutic index Toxicity 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 229940098465 tincture Drugs 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 238000005757 von Pechmann cycloaddition reaction Methods 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 1
- IOQORVDNYPOZPL-VQTJNVASSA-N (5S,6R)-5-(4-chlorophenyl)-6-cyclopropyl-3-[6-methoxy-5-(4-methylimidazol-1-yl)pyridin-2-yl]-5,6-dihydro-2H-1,2,4-oxadiazine Chemical compound ClC1=CC=C(C=C1)[C@@H]1NC(=NO[C@@H]1C1CC1)C1=NC(=C(C=C1)N1C=NC(=C1)C)OC IOQORVDNYPOZPL-VQTJNVASSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- FLIRDXXWUGWZRV-UHFFFAOYSA-N 1-(2,4-dichlorophenyl)-3-(6-oxo-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-4-yl)thiourea Chemical compound CC(C)OC1=CC=C2C=3CCCCC=3C(=O)OC2=C1NC(=S)NC1=CC=C(Cl)C=C1Cl FLIRDXXWUGWZRV-UHFFFAOYSA-N 0.000 description 1
- BVFFWZQVQLXZDU-UHFFFAOYSA-N 1-(6-oxo-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-2-yl)-3-phenylurea Chemical compound CC(C)OC1=CC=2OC(=O)C=3CCCCC=3C=2C=C1NC(=O)NC1=CC=CC=C1 BVFFWZQVQLXZDU-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- JPCWWKUMDUWKLQ-UHFFFAOYSA-N 10-(3,4-dimethoxyphenyl)-1,2,3,4-tetrahydroisochromeno[4,3-g][1,4]benzoxazine-5,9-dione Chemical compound C1=C(OC)C(OC)=CC=C1C(C(OC1=C2)=O)=NC1=CC1=C2OC(=O)C2=C1CCCC2 JPCWWKUMDUWKLQ-UHFFFAOYSA-N 0.000 description 1
- RBBRWJOBKWCWDG-UHFFFAOYSA-N 10-[4-(trifluoromethyl)phenyl]-1,2,3,4-tetrahydroisochromeno[4,3-g][1,4]benzoxazine-5,9-dione Chemical compound C1=CC(C(F)(F)F)=CC=C1C(C(OC1=C2)=O)=NC1=CC1=C2OC(=O)C2=C1CCCC2 RBBRWJOBKWCWDG-UHFFFAOYSA-N 0.000 description 1
- VRIHUXNIUAHEDX-UHFFFAOYSA-N 10-phenyl-1,2,3,4-tetrahydroisochromeno[4,3-g][1,4]benzoxazine-5,9-dione Chemical compound N=1C2=CC=3C=4CCCCC=4C(=O)OC=3C=C2OC(=O)C=1C1=CC=CC=C1 VRIHUXNIUAHEDX-UHFFFAOYSA-N 0.000 description 1
- RCVYNUPZCBQBER-UHFFFAOYSA-N 10-propan-2-yl-1,2,3,4-tetrahydroisochromeno[4,3-f][1,3]benzoxazole-5,9-dione Chemical compound C1CCCC2=C1C(C=C1N(C(OC1=C1)=O)C(C)C)=C1OC2=O RCVYNUPZCBQBER-UHFFFAOYSA-N 0.000 description 1
- ICRFZLSOVLSKKX-UHFFFAOYSA-N 11-chloro-2-methylsulfanyl-6,7,8,9-tetrahydroisochromeno[3,4-e][1,3]benzoxazol-5-one Chemical compound C1CCCC2=C1C(C=C(Cl)C1=C3N=C(O1)SC)=C3OC2=O ICRFZLSOVLSKKX-UHFFFAOYSA-N 0.000 description 1
- MPCNVVVBDDPGKR-UHFFFAOYSA-N 2,3,4,10-tetrahydro-1h-isochromeno[4,3-f][1,3]benzoxazole-5,9-dione Chemical compound C1CCCC2=C1C(C=C1NC(OC1=C1)=O)=C1OC2=O MPCNVVVBDDPGKR-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- ZWNJGORFKROHHX-UHFFFAOYSA-N 2-(difluoromethoxy)-3-methoxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(OC(F)F)C(OC)=C1 ZWNJGORFKROHHX-UHFFFAOYSA-N 0.000 description 1
- ZRHGDWANNIINBF-UHFFFAOYSA-N 2-(methylamino)-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(C=C(C(=C1)OC(C)C)NC)=C1OC2=O ZRHGDWANNIINBF-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- NSAPNNPWPTVVMP-UHFFFAOYSA-N 2-acetyl-3-methoxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(C(C)=O)C(OC)=C1 NSAPNNPWPTVVMP-UHFFFAOYSA-N 0.000 description 1
- JMNWVSRNZDGZBA-UHFFFAOYSA-N 2-amino-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(N)C(OC(C)C)=C1 JMNWVSRNZDGZBA-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- MDRWCSFCKRWHIW-UHFFFAOYSA-N 2-chloro-3-[2-hydroxy-3-(propan-2-ylamino)propoxy]-7,8,9,10-tetrahydrobenzo[c]chromen-6-one;hydrochloride Chemical compound Cl.C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(OCC(O)CNC(C)C)=C1 MDRWCSFCKRWHIW-UHFFFAOYSA-N 0.000 description 1
- ZTXSCJJSEVGHOJ-UHFFFAOYSA-N 2-chloro-3-[3-(dimethylamino)-2-hydroxypropoxy]-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(OCC(O)CN(C)C)=C1 ZTXSCJJSEVGHOJ-UHFFFAOYSA-N 0.000 description 1
- OGZLECOCHBEKOB-UHFFFAOYSA-N 2-chloro-3-hydroxy-8-(trifluoromethyl)-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1C(C(F)(F)F)CCC2=C1C(=O)OC1=C2C=C(Cl)C(O)=C1 OGZLECOCHBEKOB-UHFFFAOYSA-N 0.000 description 1
- ILTYIUFYFRZSNJ-UHFFFAOYSA-N 2-chloro-3-methylsulfanyl-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(SC)=C1 ILTYIUFYFRZSNJ-UHFFFAOYSA-N 0.000 description 1
- QHYYMNFSAQRWHZ-UHFFFAOYSA-N 2-chloro-3-propan-2-yloxy-8-pyridin-3-yl-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CC=2C=3C=C(Cl)C(OC(C)C)=CC=3OC(=O)C=2CC1C1=CC=CN=C1 QHYYMNFSAQRWHZ-UHFFFAOYSA-N 0.000 description 1
- KKIDANOEXRVWOT-UHFFFAOYSA-N 2-chloro-3-propoxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(OCCC)=C1 KKIDANOEXRVWOT-UHFFFAOYSA-N 0.000 description 1
- AZNKHYVDGWJNSC-UHFFFAOYSA-N 2-chloro-3-pyrrolidin-1-yl-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound ClC1=CC=2C=3CCCCC=3C(=O)OC=2C=C1N1CCCC1 AZNKHYVDGWJNSC-UHFFFAOYSA-N 0.000 description 1
- GXRHHLKRGDQDHV-UHFFFAOYSA-N 2-chloro-n-(6-oxo-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-4-yl)acetamide Chemical compound C1CCCC2=C1C1=CC=C(OC(C)C)C(NC(=O)CCl)=C1OC2=O GXRHHLKRGDQDHV-UHFFFAOYSA-N 0.000 description 1
- KLRXGSCAUJWCLY-UHFFFAOYSA-N 2-ethyl-6,7,8,9-tetrahydroisochromeno[3,4-e][1,3]benzoxazol-5-one Chemical compound C1CCCC2=C1C(C=CC1=C3N=C(O1)CC)=C3OC2=O KLRXGSCAUJWCLY-UHFFFAOYSA-N 0.000 description 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 1
- UMEAKYINOVAZMS-UHFFFAOYSA-N 2-methyl-n-(6-oxo-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-2-yl)propanamide Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(NC(=O)C(C)C)C(OC(C)C)=C1 UMEAKYINOVAZMS-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- OYYOPGHIKRMARM-UHFFFAOYSA-N 3-(3-anilino-2-hydroxypropoxy)-2-chloro-7,8,9,10-tetrahydrobenzo[c]chromen-6-one;hydrochloride Chemical compound Cl.C=1C=2OC(=O)C=3CCCCC=3C=2C=C(Cl)C=1OCC(O)CNC1=CC=CC=C1 OYYOPGHIKRMARM-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- OKTBCSNAARBUOP-UHFFFAOYSA-N 3-(adamantane-1-carbonyl)-7-(1,3-oxazol-2-yl)chromen-2-one Chemical compound C1C(C2)CC(C3)CC2CC13C(=O)C(C(OC1=C2)=O)=CC1=CC=C2C1=NC=CO1 OKTBCSNAARBUOP-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- ZKRRDDKQKDYYNJ-UHFFFAOYSA-N 3-hydroxy-2-nitro-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C([N+]([O-])=O)C(O)=C1 ZKRRDDKQKDYYNJ-UHFFFAOYSA-N 0.000 description 1
- OCRPPMHVRQIWOS-UHFFFAOYSA-N 3-hydroxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C1=CC=C(O)C=C1OC2=O OCRPPMHVRQIWOS-UHFFFAOYSA-N 0.000 description 1
- QTSPNXWEPBTGTP-UHFFFAOYSA-N 3-methyl-6,7,8,9-tetrahydroisochromeno[3,4-e][1,3]benzoxazole-2,5-dione Chemical compound C1CCCC2=C1C(C=CC1=C3N(C(O1)=O)C)=C3OC2=O QTSPNXWEPBTGTP-UHFFFAOYSA-N 0.000 description 1
- PENKNHHOZORLHF-UHFFFAOYSA-N 3-pyridin-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1=CC=2C=3CCCCC=3C(=O)OC=2C=C1OC1=CC=CC=N1 PENKNHHOZORLHF-UHFFFAOYSA-N 0.000 description 1
- QWDYKUBAAZRJNP-UHFFFAOYSA-N 4-(methylamino)-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C(C=CC(OC(C)C)=C1NC)=C1OC2=O QWDYKUBAAZRJNP-UHFFFAOYSA-N 0.000 description 1
- MINMDCMSHDBHKG-UHFFFAOYSA-N 4-[4-[[6-methoxy-2-(2-methoxyimidazo[2,1-b][1,3,4]thiadiazol-6-yl)-1-benzofuran-4-yl]oxymethyl]-5-methyl-1,3-thiazol-2-yl]morpholine Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(=C(S1)C)N=C1N1CCOCC1 MINMDCMSHDBHKG-UHFFFAOYSA-N 0.000 description 1
- BMLVUCIIYZQUCS-UHFFFAOYSA-N 4-amino-2-chloro-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-6-one Chemical compound C1CCCC2=C1C1=CC(Cl)=C(OC(C)C)C(N)=C1OC2=O BMLVUCIIYZQUCS-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- QKVSKOAAEANZFC-UHFFFAOYSA-N 4-methoxy-2-methyl-8,9,10,11-tetrahydroisochromeno[4,3-e][1,3]benzoxazol-7-one Chemical compound C1CCCC2=C1C(=O)OC(C=C1OC)=C2C2=C1OC(C)=N2 QKVSKOAAEANZFC-UHFFFAOYSA-N 0.000 description 1
- GYQZUCALAJVYEM-UHFFFAOYSA-N 4-methoxy-2-sulfanylidene-8,9,10,11-tetrahydro-1h-isochromeno[4,3-e][1,3]benzoxazol-7-one Chemical compound C1CCCC2=C1C(=O)OC(C=C1OC)=C2C2=C1OC(=S)N2 GYQZUCALAJVYEM-UHFFFAOYSA-N 0.000 description 1
- FHDIGESZJTVURD-UHFFFAOYSA-N 4-methoxy-8,9,10,11-tetrahydro-1h-isochromeno[4,3-e][1,3]benzoxazole-2,7-dione Chemical compound C1CCCC2=C1C(=O)OC(C=C1OC)=C2C2=C1OC(=O)N2 FHDIGESZJTVURD-UHFFFAOYSA-N 0.000 description 1
- WBNZLLNSUOECCB-UHFFFAOYSA-N 4-methyl-N-(6-oxo-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-4-yl)benzenesulfonamide Chemical compound S(=O)(=O)(C1=CC=C(C)C=C1)NC=1C(=CC=C2C3=C(C(OC12)=O)CCCC3)OC(C)C WBNZLLNSUOECCB-UHFFFAOYSA-N 0.000 description 1
- OTZAZTVREGVWMW-UHFFFAOYSA-N 4-oxo-4-[(6-oxo-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-2-yl)amino]butanoic acid Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(NC(=O)CCC(O)=O)C(OC(C)C)=C1 OTZAZTVREGVWMW-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- GEDJJYADBOMTLP-UHFFFAOYSA-N 6-chloro-7-[(4-fluorophenyl)methoxy]-4-phenylchromen-2-one Chemical compound C1=CC(F)=CC=C1COC(C(=C1)Cl)=CC2=C1C(C=1C=CC=CC=1)=CC(=O)O2 GEDJJYADBOMTLP-UHFFFAOYSA-N 0.000 description 1
- MHGKLADKKBWJBF-UHFFFAOYSA-N 6-chloro-7-propan-2-yloxy-4-(trifluoromethyl)chromen-2-one Chemical compound O1C(=O)C=C(C(F)(F)F)C2=C1C=C(OC(C)C)C(Cl)=C2 MHGKLADKKBWJBF-UHFFFAOYSA-N 0.000 description 1
- FYSIHIGVKRIXJQ-UHFFFAOYSA-N 6-chloro-7-propan-2-yloxy-4-pyridin-2-ylchromen-2-one Chemical compound C1=2C=C(Cl)C(OC(C)C)=CC=2OC(=O)C=C1C1=CC=CC=N1 FYSIHIGVKRIXJQ-UHFFFAOYSA-N 0.000 description 1
- YTMAPJKHKDHMNG-UHFFFAOYSA-N 6-chloro-7-propan-2-yloxy-4-pyridin-4-ylchromen-2-one Chemical compound C1=2C=C(Cl)C(OC(C)C)=CC=2OC(=O)C=C1C1=CC=NC=C1 YTMAPJKHKDHMNG-UHFFFAOYSA-N 0.000 description 1
- TVKNXKLYVUVOCV-UHFFFAOYSA-N 6H-dibenzo[b,d]pyran-6-one Chemical compound C12=CC=CC=C2C(=O)OC2=C1C=CC=C2 TVKNXKLYVUVOCV-UHFFFAOYSA-N 0.000 description 1
- OUGRNQUOCHWEQD-UHFFFAOYSA-N 7-[(4-fluorophenyl)methoxy]-4-phenylchromen-2-one Chemical compound C1=CC(F)=CC=C1COC1=CC=C(C(=CC(=O)O2)C=3C=CC=CC=3)C2=C1 OUGRNQUOCHWEQD-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- RIAHQASCFAVZHU-UHFFFAOYSA-N 9-(1-adamantyl)-1,2,3,4-tetrahydroisochromeno[4,3-f][1,3]benzoxazol-5-one Chemical compound C1C(C2)CC(C3)CC2CC13C(OC1=C2)=NC1=CC1=C2OC(=O)C2=C1CCCC2 RIAHQASCFAVZHU-UHFFFAOYSA-N 0.000 description 1
- ZTNJQZMSFAJQAD-UHFFFAOYSA-N 9-[[4-(dimethylamino)phenyl]methyl]-1,2,3,4-tetrahydroisochromeno[4,3-f][1,3]benzoxazol-5-one Chemical compound C1=CC(N(C)C)=CC=C1CC(OC1=C2)=NC1=CC1=C2OC(=O)C2=C1CCCC2 ZTNJQZMSFAJQAD-UHFFFAOYSA-N 0.000 description 1
- DFCCTQWXGIBIHJ-UHFFFAOYSA-N 9-anilino-1,2,3,4-tetrahydroisochromeno[4,3-f][1,3]benzoxazol-5-one Chemical compound N=1C2=CC=3C=4CCCCC=4C(=O)OC=3C=C2OC=1NC1=CC=CC=C1 DFCCTQWXGIBIHJ-UHFFFAOYSA-N 0.000 description 1
- ONWOACGFANBNPX-UHFFFAOYSA-N 9-benzoyl-1,2,3,4-tetrahydroisochromeno[4,3-f][1,3]benzoxazol-5-one Chemical compound N=1C2=CC=3C=4CCCCC=4C(=O)OC=3C=C2OC=1C(=O)C1=CC=CC=C1 ONWOACGFANBNPX-UHFFFAOYSA-N 0.000 description 1
- ODDWBGOGGZJHKA-UHFFFAOYSA-N 9-ethoxy-1,2,3,4-tetrahydroisochromeno[4,3-f][1,3]benzoxazol-5-one Chemical compound C1CCCC2=C1C(C=C1N=C(OC1=C1)OCC)=C1OC2=O ODDWBGOGGZJHKA-UHFFFAOYSA-N 0.000 description 1
- SFYVAZFATQRFLK-UHFFFAOYSA-N 9-ethyl-1,2,3,4-tetrahydroisochromeno[4,3-f][1,3]benzoxazol-5-one Chemical compound C1CCCC2=C1C(C=C1N=C(OC1=C1)CC)=C1OC2=O SFYVAZFATQRFLK-UHFFFAOYSA-N 0.000 description 1
- JHYOPKMZQOGFRP-UHFFFAOYSA-N 9-methyl-1,2,3,4-tetrahydroisochromeno[4,3-f][1,3]benzoxazol-5-one Chemical compound C1CCCC2=C1C(C=C1N=C(OC1=C1)C)=C1OC2=O JHYOPKMZQOGFRP-UHFFFAOYSA-N 0.000 description 1
- QIVKCGCCENJXJB-UHFFFAOYSA-N 9-phenyl-1,2,3,4-tetrahydroisochromeno[4,3-f][1,3]benzoxazol-5-one Chemical compound N=1C2=CC=3C=4CCCCC=4C(=O)OC=3C=C2OC=1C1=CC=CC=C1 QIVKCGCCENJXJB-UHFFFAOYSA-N 0.000 description 1
- ONVMNPBPFQCPQR-UHFFFAOYSA-N 9-pyridin-4-yl-1,2,3,4-tetrahydroisochromeno[4,3-f][1,3]benzoxazol-5-one Chemical compound N=1C2=CC=3C=4CCCCC=4C(=O)OC=3C=C2OC=1C1=CC=NC=C1 ONVMNPBPFQCPQR-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 238000012371 Aseptic Filling Methods 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000031638 Body Weight Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 244000183685 Citrus aurantium Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 240000002319 Citrus sinensis Species 0.000 description 1
- 235000005976 Citrus sinensis Nutrition 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000020897 Formins Human genes 0.000 description 1
- 108091022623 Formins Proteins 0.000 description 1
- 239000012586 G-5 Supplement Substances 0.000 description 1
- 102100039289 Glial fibrillary acidic protein Human genes 0.000 description 1
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 1
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 1
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 102000006541 Ionotropic Glutamate Receptors Human genes 0.000 description 1
- 108010008812 Ionotropic Glutamate Receptors Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 102100036837 Metabotropic glutamate receptor 2 Human genes 0.000 description 1
- 102100038352 Metabotropic glutamate receptor 3 Human genes 0.000 description 1
- 102100038300 Metabotropic glutamate receptor 6 Human genes 0.000 description 1
- 102100038294 Metabotropic glutamate receptor 7 Human genes 0.000 description 1
- 102100037636 Metabotropic glutamate receptor 8 Human genes 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 108010064983 Ovomucin Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- YNPNZTXNASCQKK-UHFFFAOYSA-N Phenanthrene Natural products C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000014384 Type C Phospholipases Human genes 0.000 description 1
- 108010079194 Type C Phospholipases Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 230000003140 astrocytic effect Effects 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 150000001538 azepines Chemical class 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Substances N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012742 biochemical analysis Methods 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000337 buffer salt Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940003871 calcium ion Drugs 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 229940078456 calcium stearate Drugs 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- NBYQXBYMEUOBON-UHFFFAOYSA-N carbamothioyl chloride Chemical compound NC(Cl)=S NBYQXBYMEUOBON-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229960004424 carbon dioxide Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 210000000782 cerebellar granule cell Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940127573 compound 38 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125844 compound 46 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940095079 dicalcium phosphate anhydrous Drugs 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
- 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000007720 emulsion polymerization reaction Methods 0.000 description 1
- JJJFUHOGVZWXNQ-UHFFFAOYSA-N enbucrilate Chemical compound CCCCOC(=O)C(=C)C#N JJJFUHOGVZWXNQ-UHFFFAOYSA-N 0.000 description 1
- 229950010048 enbucrilate Drugs 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
- FGSGHBPKHFDJOP-UHFFFAOYSA-N ethyl 2-oxocyclohexane-1-carboxylate Chemical compound CCOC(=O)C1CCCCC1=O FGSGHBPKHFDJOP-UHFFFAOYSA-N 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 150000002462 imidazolines Chemical class 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- YTBCYGLUQRQAOS-UHFFFAOYSA-N indeno[5,4-a]quinolizine-2,5-dione Chemical compound C1=CC=CN2C(C=C3C4=CC(C=C4C=CC3=C12)=O)=O YTBCYGLUQRQAOS-UHFFFAOYSA-N 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000011630 iodine Chemical group 0.000 description 1
- 229910052740 iodine Chemical group 0.000 description 1
- 230000001057 ionotropic effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 150000002545 isoxazoles Chemical class 0.000 description 1
- 150000002546 isoxazolidines Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 108010038421 metabotropic glutamate receptor 2 Proteins 0.000 description 1
- 108010038445 metabotropic glutamate receptor 3 Proteins 0.000 description 1
- 108010038450 metabotropic glutamate receptor 6 Proteins 0.000 description 1
- 108010038449 metabotropic glutamate receptor 7 Proteins 0.000 description 1
- 108010038448 metabotropic glutamate receptor 8 Proteins 0.000 description 1
- 102000006239 metabotropic receptors Human genes 0.000 description 1
- 108020004083 metabotropic receptors Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- PHWISQNXPLXQRU-UHFFFAOYSA-N n,n-dimethylcarbamothioyl chloride Chemical compound CN(C)C(Cl)=S PHWISQNXPLXQRU-UHFFFAOYSA-N 0.000 description 1
- SXNYDQWNMJRLOS-UHFFFAOYSA-N n-(2-chloro-6-oxo-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-4-yl)benzamide Chemical compound CC(C)OC1=C(Cl)C=C2C=3CCCCC=3C(=O)OC2=C1NC(=O)C1=CC=CC=C1 SXNYDQWNMJRLOS-UHFFFAOYSA-N 0.000 description 1
- WDZFZZZLJUSPMF-UHFFFAOYSA-N n-(2-chloro-6-oxo-7,8,9,10-tetrahydrobenzo[c]chromen-3-yl)acetamide Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(Cl)C(NC(=O)C)=C1 WDZFZZZLJUSPMF-UHFFFAOYSA-N 0.000 description 1
- MIMNDVRBYTWMIW-UHFFFAOYSA-N n-(6-oxo-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-4-yl)methanesulfonamide Chemical compound C1CCCC2=C1C1=CC=C(OC(C)C)C(NS(C)(=O)=O)=C1OC2=O MIMNDVRBYTWMIW-UHFFFAOYSA-N 0.000 description 1
- RJPIDJGRZCSRCU-UHFFFAOYSA-N n-acetyl-n-(6-oxo-3-propan-2-yloxy-7,8,9,10-tetrahydrobenzo[c]chromen-2-yl)acetamide Chemical compound C1CCCC2=C1C(=O)OC1=C2C=C(N(C(C)=O)C(C)=O)C(OC(C)C)=C1 RJPIDJGRZCSRCU-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- HWYHDWGGACRVEH-UHFFFAOYSA-N n-methyl-n-(4-pyrrolidin-1-ylbut-2-ynyl)acetamide Chemical compound CC(=O)N(C)CC#CCN1CCCC1 HWYHDWGGACRVEH-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 210000000478 neocortex Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 150000004866 oxadiazoles Chemical class 0.000 description 1
- 150000002917 oxazolidines Chemical class 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035778 pathophysiological process Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920002721 polycyanoacrylate Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003216 pyrazines Chemical class 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 150000004892 pyridazines Chemical class 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 102200160920 rs35304565 Human genes 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000013391 scatchard analysis Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002265 sensory receptor cell Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- 150000003548 thiazolidines Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- ORHBXUUXSCNDEV-UHFFFAOYSA-N umbelliferone Chemical compound C1=CC(=O)OC2=CC(O)=CC=C21 ORHBXUUXSCNDEV-UHFFFAOYSA-N 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/78—Ring systems having three or more relevant rings
- C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US72931205P | 2005-10-21 | 2005-10-21 | |
| US60/729,312 | 2005-10-21 | ||
| PCT/GB2006/003888 WO2007045876A1 (fr) | 2005-10-21 | 2006-10-19 | Chromenones et leur utilisation en tant que modulateurs des recepteurs metabotropes au glutamate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2620248A1 true CA2620248A1 (fr) | 2007-04-26 |
Family
ID=37487556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002620248A Abandoned CA2620248A1 (fr) | 2005-10-21 | 2006-10-19 | Chromenones et leur utilisation en tant que modulateurs des recepteurs metabotropes au glutamate |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1957475A1 (fr) |
| AU (1) | AU2006303037A1 (fr) |
| CA (1) | CA2620248A1 (fr) |
| IL (1) | IL190740A0 (fr) |
| WO (1) | WO2007045876A1 (fr) |
| ZA (1) | ZA200801641B (fr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2032701T3 (da) | 2006-06-23 | 2014-02-10 | Alethia Biotherapeutics Inc | Polynukleotider og polypeptider, der er inddraget i cancer |
| WO2009118338A2 (fr) * | 2008-03-27 | 2009-10-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Utilisation d’un composé de type polyphénolique pour prévenir ou traiter une maladie neurodégénérative d’expansion de polyglutamine |
| CA2721927C (fr) | 2008-04-21 | 2014-01-28 | Otonomy, Inc. | Preparations auriculaires de traitement de maladies et etats otiques |
| US11969501B2 (en) | 2008-04-21 | 2024-04-30 | Dompé Farmaceutici S.P.A. | Auris formulations for treating otic diseases and conditions |
| US8496957B2 (en) | 2008-07-21 | 2013-07-30 | Otonomy, Inc | Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders |
| US9173864B2 (en) | 2008-10-22 | 2015-11-03 | House Ear Institute | Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor |
| KR20110084280A (ko) | 2008-11-03 | 2011-07-21 | 알레시아 바이오쎄라퓨틱스 인코포레이티드 | 종양 항원의 생물 활성을 특이적으로 차단하는 항체 |
| US8399460B2 (en) | 2009-10-27 | 2013-03-19 | Astrazeneca Ab | Chromenone derivatives |
| KR101993259B1 (ko) | 2011-03-31 | 2019-06-27 | 에이디씨 테라퓨틱스 에스에이 | 신장 결합 항원 １에 대한 항체 및 이의 항원 결합 단편 |
| FR2973703A1 (fr) * | 2011-04-08 | 2012-10-12 | Univ Provence Aix Marseille 1 | Derives de 4-arylcoumarine et de 4-arylquinoleine, leurs utilisations therapeutiques et leur procede de synthese |
| EA201992513A1 (ru) | 2012-01-09 | 2020-05-31 | Адс Терапьютикс Са | Способ лечения рака груди |
| WO2014129989A1 (fr) * | 2013-02-21 | 2014-08-28 | Fargem Farmasöti̇k Araştirma Geli̇şti̇rme Merkezi̇ Sanayi̇ Ve Ti̇caret A.Ş. | 6h-benzo[c]chromén-6-ones 3 substituées et 7,8,9,10-tétrahydro-6h-benzo[c]chromén-6-ones 3 substituées contre la démence sénile |
| EP2792359A1 (fr) * | 2013-04-19 | 2014-10-22 | Merz Pharma GmbH & Co. KGaA | Traitement de la dyskinésie induite par L-DOPA avec OPC-14523 ou OPC-34712 |
| WO2019055528A1 (fr) | 2017-09-13 | 2019-03-21 | Cerepeut, Inc. | Nouveau composé à petites molécules |
| CN110818669B (zh) * | 2019-11-25 | 2022-11-29 | 中国医学科学院药用植物研究所海南分所 | 沉香四氢2-（2-苯乙基）色酮类化合物及其分离方法和应用 |
| CN114874174B (zh) * | 2022-02-25 | 2023-09-22 | 云南民族大学 | 具有抗乙肝病毒和冠状病毒作用的苯并二氢吡喃类化合物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999026927A2 (fr) * | 1997-11-21 | 1999-06-03 | Nps Pharmaceuticals, Inc. | Antagonistes des recepteurs du glutamate metabotropes, utilises pour le traitement de maladies du systeme nerveux central |
| JPWO2002102807A1 (ja) * | 2001-06-14 | 2004-09-30 | 萬有製薬株式会社 | 新規イソキサゾロピリドン誘導体及びその用途 |
| TWI301760B (en) * | 2004-02-27 | 2008-10-11 | Merz Pharma Gmbh & Co Kgaa | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
-
2006
- 2006-10-19 AU AU2006303037A patent/AU2006303037A1/en not_active Abandoned
- 2006-10-19 CA CA002620248A patent/CA2620248A1/fr not_active Abandoned
- 2006-10-19 WO PCT/GB2006/003888 patent/WO2007045876A1/fr active Application Filing
- 2006-10-19 EP EP06794829A patent/EP1957475A1/fr not_active Withdrawn
-
2008
- 2008-02-19 ZA ZA200801641A patent/ZA200801641B/xx unknown
- 2008-04-09 IL IL190740A patent/IL190740A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1957475A1 (fr) | 2008-08-20 |
| AU2006303037A1 (en) | 2007-04-26 |
| WO2007045876A1 (fr) | 2007-04-26 |
| ZA200801641B (en) | 2008-12-31 |
| IL190740A0 (en) | 2009-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2620248A1 (fr) | Chromenones et leur utilisation en tant que modulateurs des recepteurs metabotropes au glutamate | |
| AU2006283359B2 (en) | Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors | |
| US20070299113A1 (en) | Metabotropic glutamate receptor modulators | |
| CA2556653C (fr) | Tetrahydroquinolinones et leur utilisation comme antagonistes des recepteurs de glutamate metabotropique | |
| US20080032998A1 (en) | Pyrazolopyrimidines, a process for their preparation and their use as medicine | |
| US20110003820A1 (en) | Pyrazolopyrimidines, a process for their preparation and their use as medicine | |
| WO2012052451A1 (fr) | Modulateurs des récepteurs métabotropes au glutamate | |
| WO2012085166A1 (fr) | Modulateurs des récepteurs glutamatergiques métabotropes | |
| WO2007023245A1 (fr) | Tetrahydroquinolinones et leur utilisation en tant que modulateurs des recepteurs metabotropes du glutamate | |
| US7550482B2 (en) | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | |
| US20060004001A1 (en) | Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors | |
| WO2008035049A1 (fr) | Adamantanyl-(cyclopropyl)-cétones utilisées en tant que modulateurs du récepteur métabotropique du glutamate | |
| MXPA06009564A (en) | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |